<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512302</url>
  </required_header>
  <id_info>
    <org_study_id>SUN101-105</org_study_id>
    <nct_id>NCT02512302</nct_id>
  </id_info>
  <brief_title>Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).</brief_title>
  <acronym>GOLDEN7</acronym>
  <official_title>A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the amount of medicine absorbed in the
      lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated
      charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, single-dose per dosing period, five-way crossover study in
      subjects 40 to 70 years of age with a diagnosis of moderate to severe COPD per Global
      Initiative for Chronic Obstructive Lung Disease guidelines. After a subject provides consent
      for study participation, there will be a Screening Period lasting up to 3 weeks to determine
      study eligibility and to allow for appropriate washout of prohibited medications.

      Eligible subjects will be randomized to one of 10 treatment Sequences. There will be a
      minimum of a 7-day washout period between each treatment visit. At each visit, subjects will
      receive one dose of study medication according to the sequence assigned.

      Subjects with a ≥ 20% decrease in forced expiratory volume in one second (FEV1) based on
      review of the Visit predose value compared with the Screening value will be evaluated by the
      investigator for continuation in the study.

      Subjects taking theophylline will not be able to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 24 Hours (AUC0_24)</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Infinity (AUC0_infinity)</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / | λz | Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>calculated as Dose/(AUC0-inf*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>calculated as Dose/(AUC0-∞* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Cmax for Seebri and SUN-101.</measure>
    <time_frame>up to week 5</time_frame>
    <description>Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101</measure>
    <time_frame>up to week 5</time_frame>
    <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor* (AUC0-∞ = AUC0-last+ Clast / | λz | ) Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</measure>
    <time_frame>Up to Week 5</time_frame>
    <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>SUN-101 via eFlow nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg glycopyrrolate via Electronic Nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUN-101 via eFlow nebulizer with activated charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seebri® Breezhaler®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seebri® Breezhaler® with activated charcoal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>: Glycopyrrolate Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mcg glycopyrrolate via IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 via eFlow nebulizer</intervention_name>
    <description>50 mcg glycopyrrolate via Electronic Nebulizer</description>
    <arm_group_label>SUN-101 via eFlow nebulizer</arm_group_label>
    <other_name>Glycopyrrolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 via eFlow nebulizer with activated charcoal</intervention_name>
    <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
    <arm_group_label>SUN-101 via eFlow nebulizer with activated charcoal</arm_group_label>
    <other_name>Glycopyrrolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seebri® Breezhaler®</intervention_name>
    <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
    <arm_group_label>Seebri® Breezhaler®</arm_group_label>
    <other_name>glycopyrronium, glycopyrronium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seebri® Breezhaler® with activated charcoal</intervention_name>
    <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
    <arm_group_label>Seebri® Breezhaler® with activated charcoal</arm_group_label>
    <other_name>glycopyrronium, glycopyrronium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Injection</intervention_name>
    <description>50 mcg glycopyrrolate via IV</description>
    <arm_group_label>: Glycopyrrolate Injection</arm_group_label>
    <other_name>Glycopyrrolate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 40 to 70 years-old, inclusive.

          2. A clinical diagnosis of moderate to severe COPD according to the GOLD 2014 guidelines.

          3. Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least
             1 pack/day for 10 years, or equivalent).

          4. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 30% and ≤ 80%
             of predicted normal during the Screening Period.

          5. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤
             0.70 during the Screening Period.

          6. Ability to perform reproducible spirometry according to the American Thoracic Society
             (ATS) and/or European Respiratory Society (ERS) guidelines (2005).

          7. Subject, if female ≤ 70 years of age and of child bearing potential, must have a
             negative urine pregnancy test at Visit 1. Females of childbearing potential must be
             instructed to and agree to avoid pregnancy during the study and must use an acceptable
             method of birth control: a) an oral contraceptive, an intrauterine device (IUD),
             implantable contraceptive, transdermal or injectable contraceptive for at least 1
             month prior to entering the study with continued use throughout the study and for
             thirty days following participation; b) barrier method of contraception, eg, condom
             and /or diaphragm with spermicide while participating in the study; and/or c)
             abstinence.

          8. Willing and able to remain at the study site for at least 24 hours for each treatment
             day.

          9. Willing and able to provide written informed consent.

         10. Willing and able to attend all study visits and adhere to all study assessments and
             procedures.

        Exclusion Criteria:

          1. Severe comorbidities including unstable cardiac or pulmonary disease or any other
             medical conditions that would, in the opinion of the Investigator, preclude the
             subject from safely completing the required tests or the study, or is likely to result
             in disease progression that would require withdrawal of the subject, included but not
             limited to the following:

               -  Unstable ischemic heart disease (diagnosis of myocardial infarction or admission
                  for acute coronary syndrome) within 6 months of screening.

               -  Unstable cardiac arrhythmia or heart failure (change in treatment plan) within 6
                  months.

               -  Treatment for diabetes mellitus within 6 months of screening.

          2. Current evidence or history of a clinically significant abnormality of cardiac rhythm
             and/or conduction findings.

          3. Concomitant clinically significant respiratory disease other than COPD (eg, asthma,
             tuberculosis, bronchiectasis, or other non-specific pulmonary disease).

          4. History of malignancy of any organ system treated or untreated within the past 5
             years, with the exception of localized basal cell carcinoma of the skin.

          5. Recent history of COPD exacerbation requiring hospitalization or need for increased
             treatments for COPD within 6 weeks prior to the Screening Period.

          6. Use of daily oxygen therapy &gt; 10 hours per day.

          7. Use of oral, intravenous, or intramuscular steroids within 3 months prior to the
             Screening Period.

          8. Respiratory tract infection within 6 weeks prior to or during the Screening Period.

          9. Significant blood loss (&gt; 500 mL) or donated blood within 60 days preceding screening
             or plans to donate blood within 60 days after completing the study.

         10. History of or clinically significant ongoing bladder outflow obstruction or history of
             catheterization for relief of bladder outflow obstruction within the previous 6
             months.

         11. History of narrow-angle glaucoma.

         12. Prolonged QTc interval (&gt; 450 msec for males and &gt; 470 msec for females) during the
             Screening Period, or history of long QT syndrome.

         13. Recent documented history (previous 12 months) of substance abuse.

         14. .Positive urine drug screen at Visit 1 provided the subject is unable to produce a
             valid medical rationale for the test result (eg, prescription medication).

         15. Positive HbsAg, Hepatitis C antibody, or HIV 1/2 antibody test at Screening.

         16. History of hypersensitivity or intolerance to aerosol medications, β2-agonists,
             anticholinergics, or sympathomimetic amines.

         17. Significant psychiatric disease that would likely result in the subject not being able
             to complete the study, in the opinion of the Investigator.

         18. Participation in another investigational drug study where drug was received within 30
             days prior to the Screening Period, or current participation in another
             investigational drug trial in which study treatment is being administered, including a
             SUN-101 study

         19. Previously received SUN-101 (active treatment; formerly known as EP-101).

         20. Previously received any glycopyrrolate product within 28 days of Screening.

         21. Subject is taking theophylline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Global Clinical, Respiratory and Bio-threapeutics</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Anne Street Medical Center</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines evaluation Unit Ltd.</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>January 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>September 27, 2018</last_update_submitted>
  <last_update_submitted_qc>September 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible subjects will be randomized to one of 10 treatment sequences. There will be a minimum of a 7-day washout period between each treatment visit. At each visit, subjects will receive one dose of study medication according to the sequence assigned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group One</title>
          <description>Participants received Seebri Breezhaler with activated charcoal 63 mcg; SUN-101 50 mcg via eFlow nebulizer with activated charcoal; Glycopyrrolate injection via IV infusion; SUN-101 50 mcg via e flow nebulizer; Seebri Breezhaler 63 mcg for each of the five treatment periods</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group Two</title>
          <description>Participants received SUN-101 50 mcg via eFlow nebulizer, SUN-101 50 mcg via eFlow nebulier with activated charcoal; Seebri Breezhaler 63 mcg, Seebri Breezhaler 63 mcg with activated charcoal; Glycopyrrolate injection via IV infusion for each of the five treatment periods</description>
        </group>
        <group group_id="P3">
          <title>Treatment Group Three</title>
          <description>Participants recveived SUN-101 50 mcg via eFlow nebulizer; Seebri Breezhaler 63mcg; SUN-101 50mcg via eFlow nebulizer with activated charcoal; Glycopyrrolate injection via IV infusion; Seebri Breezerhaler 63mcg with activated charcoal for each of the five treatment periods</description>
        </group>
        <group group_id="P4">
          <title>Treatment Group Four</title>
          <description>Participants received Glycopyrrolate injection via IV infusion; Seebri Breezhaler 63mcg with activated charcoal; Seebri Breezhaler 63mcg; SUN-101 50 mcg via eFlow nebulizer with activated charcoal; SUN-101 50 mcg via eFlow nebulizer for each of the five treatment periods</description>
        </group>
        <group group_id="P5">
          <title>Treatment Group Five</title>
          <description>Participants received Seebri Breezhaler 63mcg ; Glycopyrrolate injection via IV infusion; SUN-101 50 mcg via eFlow nebulizer; Seebri Breezhaler 63mcg with activated charcoal; SUN-101 50 mcg via eFlow nebulizer with activated charcoal; for each of the five treatment periods</description>
        </group>
        <group group_id="P6">
          <title>Treatment Group Six</title>
          <description>Participants received Seebri Breezhaler 63mcg with activated charcoal ; Glycopyrrolate injection via IV infusion; SUN-101 50 mcg via eFlow nebulizer with activated charcoal; Seebri Breezhaler 63mcg SUN-101 50 mcg via eFlow nebulizer for each of the five treatment periods</description>
        </group>
        <group group_id="P7">
          <title>Treatment Group Seven</title>
          <description>Participants received Seebri Breezhaler 63mcg ; SUN-101 50 mcg via eFlow nebulizer; Glycopyrrolate injection via IV infusion; SUN-101 50 mcg via eFlow nebulizer with activated charcoal; Seebri Breezhaler 63mcg with activated charcoal for each of the five treatment periods</description>
        </group>
        <group group_id="P8">
          <title>Treatment Group Eight</title>
          <description>Participants received SUN-101 50 mcg via eFlow nebulizer with activated charcoal; SUN-101 50 mcg via eFlow nebulizer; Seebri Breezhaler 63mcg with activated charcoal; Seebri Breezhaler 63 mcg; Glycopyrrolate injection via IV infusion for each of the five treatment periods</description>
        </group>
        <group group_id="P9">
          <title>Treatment Group Nine</title>
          <description>Participants received Glycopyrrolate injection via IV infusion; Seebri Breezhaler 63 mcg; Seebri Breezhaler 63mcg with activated charcoal; SUN-101 50 mcg via eFlow nebulizer SUN-101 50 mcg via eFlow nebulizer with activated charcoalfor each of the five treatment periods</description>
        </group>
        <group group_id="P10">
          <title>Treatment Group Ten</title>
          <description>Participants received SUN-101 50 mcg via eFlow nebulizer with activated charcoal; Seebri Breezhaler 63mcg with activated charcoal; SUN-101 50 mcg via eFlow nebulizer; Glycopyrrolate injection via IV infusion;Seebri Breezhaler 63mcg for each of the five treatment periods</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>Total number of participants from all treatment groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication and have any evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
          <group group_id="O5">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication and have any evaluable PK data</population>
          <units>Pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.75" spread="51.746"/>
                    <measurement group_id="O2" value="49.27" spread="60.996"/>
                    <measurement group_id="O3" value="166.79" spread="76.348"/>
                    <measurement group_id="O4" value="148.03" spread="39.841"/>
                    <measurement group_id="O5" value="3787.47" spread="115.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 24 Hours (AUC0_24)</title>
        <description>Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication and have any evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
          <group group_id="O5">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 24 Hours (AUC0_24)</title>
          <description>Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication and have any evaluable PK data</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.23" spread="100.974"/>
                    <measurement group_id="O2" value="159.12" spread="92.720"/>
                    <measurement group_id="O3" value="472.35" spread="90.233"/>
                    <measurement group_id="O4" value="428.52" spread="46.985"/>
                    <measurement group_id="O5" value="1961.79" spread="142.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Infinity (AUC0_infinity)</title>
        <description>calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / | λz | Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
          <group group_id="O5">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Infinity (AUC0_infinity)</title>
          <description>calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / | λz | Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.23" spread="77.206"/>
                    <measurement group_id="O2" value="167.84" spread="41.208"/>
                    <measurement group_id="O3" value="607.53" spread="79.340"/>
                    <measurement group_id="O4" value="570.90" spread="63.913"/>
                    <measurement group_id="O5" value="2550.85" spread="117.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate</title>
        <description>calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate</title>
          <description>calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>Liters/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.60" spread="117.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate</title>
        <description>calculated as Dose/(AUC0-inf*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate</title>
          <description>calculated as Dose/(AUC0-inf*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.06" spread="131.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate</title>
        <description>The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate</title>
          <description>The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" lower_limit="0.08" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate</title>
        <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate</title>
          <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.998" spread="111.8589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -</title>
        <description>Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -</title>
          <description>Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.59" spread="112.339"/>
                    <measurement group_id="O2" value="179.78" spread="108.906"/>
                    <measurement group_id="O3" value="524.18" spread="99.365"/>
                    <measurement group_id="O4" value="485.99" spread="56.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</title>
        <description>calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</title>
          <description>calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.47" spread="77.206"/>
                    <measurement group_id="O2" value="297.91" spread="41.208"/>
                    <measurement group_id="O3" value="103.70" spread="79.340"/>
                    <measurement group_id="O4" value="110.35" spread="63.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</title>
        <description>calculated as Dose/(AUC0-∞* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101</title>
          <description>calculated as Dose/(AUC0-∞* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1263.63" spread="31.716"/>
                    <measurement group_id="O2" value="1668.59" spread="17.994"/>
                    <measurement group_id="O3" value="1305.30" spread="23.585"/>
                    <measurement group_id="O4" value="1708.81" spread="22.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101</title>
        <description>The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101</title>
          <description>The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.317" lower_limit="0.08" upper_limit="12.05"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.07" upper_limit="12.3"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.03" upper_limit="1.57"/>
                    <measurement group_id="O4" value="0.250" lower_limit="0.05" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101</title>
        <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101</title>
          <description>calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.554" spread="135.6286"/>
                    <measurement group_id="O2" value="5.191" spread="61.4971"/>
                    <measurement group_id="O3" value="10.378" spread="80.1891"/>
                    <measurement group_id="O4" value="14.866" spread="69.3836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Cmax for Seebri and SUN-101.</title>
        <description>Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Cmax for Seebri and SUN-101.</title>
          <description>Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>Pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.46" spread="51.746"/>
                    <measurement group_id="O2" value="78.33" spread="60.996"/>
                    <measurement group_id="O3" value="150.11" spread="76.348"/>
                    <measurement group_id="O4" value="133.22" spread="39.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101</title>
        <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101</title>
          <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.85" spread="100.974"/>
                    <measurement group_id="O2" value="253.00" spread="92.720"/>
                    <measurement group_id="O3" value="425.12" spread="90.233"/>
                    <measurement group_id="O4" value="385.67" spread="46.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101</title>
        <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101</title>
          <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.32" spread="112.339"/>
                    <measurement group_id="O2" value="285.85" spread="108.906"/>
                    <measurement group_id="O3" value="471.76" spread="99.365"/>
                    <measurement group_id="O4" value="437.39" spread="56.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101</title>
        <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor* (AUC0-∞ = AUC0-last+ Clast / | λz | ) Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
        <time_frame>up to week 5</time_frame>
        <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101</title>
          <description>Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor* (AUC0-∞ = AUC0-last+ Clast / | λz | ) Clast / | λz | is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.
The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.</description>
          <population>The Pharmacokinetic (PK) population consists of all subjects who were randomized, received study medication, and have any evaluable PK data.</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.42" spread="77.206"/>
                    <measurement group_id="O2" value="266.86" spread="41.208"/>
                    <measurement group_id="O3" value="546.78" spread="79.340"/>
                    <measurement group_id="O4" value="513.81" spread="63.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</title>
        <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
          <group group_id="O5">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</title>
          <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</title>
        <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to Week 5</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 Via eFlow Nebulizer</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
            <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
          </group>
          <group group_id="O3">
            <title>Seebri® Breezhaler®</title>
            <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
          </group>
          <group group_id="O4">
            <title>Seebri® Breezhaler® With Activated Charcoal</title>
            <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
          </group>
          <group group_id="O5">
            <title>: Glycopyrrolate Injection</title>
            <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation</title>
          <description>An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="40.7"/>
                    <measurement group_id="O5" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to week 5</time_frame>
      <desc>A serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</desc>
      <group_list>
        <group group_id="E1">
          <title>SUN-101 Via eFlow Nebulizer</title>
          <description>50 mcg glycopyrrolate via Electronic Nebulizer
SUN-101 via eFlow nebulizer: 50 mcg glycopyrrolate via Electronic Nebulizer</description>
        </group>
        <group group_id="E2">
          <title>SUN-101 Via eFlow Nebulizer With Activated Charcoal</title>
          <description>50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
SUN-101 via eFlow nebulizer with activated charcoal: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal</description>
        </group>
        <group group_id="E3">
          <title>Seebri® Breezhaler®</title>
          <description>63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Seebri® Breezhaler®: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI</description>
        </group>
        <group group_id="E4">
          <title>Seebri® Breezhaler® With Activated Charcoal</title>
          <description>: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Seebri® Breezhaler® with activated charcoal: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal</description>
        </group>
        <group group_id="E5">
          <title>: Glycopyrrolate Injection</title>
          <description>50 mcg glycopyrrolate via IV infusion
Glycopyrrolate Injection: 50 mcg glycopyrrolate via IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

